Over the past decade, immune checkpoint inhibitors, especially anti-PD-1 therapies, have revolutionized the landscape of melanoma treatment, drastically improving survival rates for many patients. However, clinical responses remain variable, with a substantial proportion of patients either exhibiting primary resistance or developing adaptive resistance over time. The complexity of the tumor microenvironment (TME) and the critical influence of the gut microbiome composition have emerged as significant factors underpinning these therapeutic outcomes. Previous attempts to modulate the gut flora via fecal microbiota transplants from responders into non-responders showed promise but lacked specificity, as the active microbial species and their metabolites responsible for these effects were largely unknown.

By isolating several Bifidobacterium species from healthy human fecal samples and systematically screening their anticancer efficacy, the investigators identified B. animalis as the most effective strain in inhibiting melanoma growth in vitro. When administered orally to murine models implanted with B16-F10 melanoma tumors, B. animalis markedly curtailed tumor size and weight without colonizing the tumor tissue, strongly implicating soluble factors in mediating its anticancer activity. Subsequent biochemical fractionation and untargeted metabolomics revealed mannose as the critical bioactive metabolite—a low molecular weight sugar below 3 kDa—secreted by B. animalis that orchestrates powerful immune activation.

Mechanistic studies into how mannose exerts its immunostimulatory properties revealed an unexpected intracellular pathway. Mannose is transported into CD8⁺ T cells via GLUT1 (glucose transporter 1), a previously established route for glucose uptake in activated T cells. Once inside, mannose directs activation of the Hippo signaling cascade, culminating in the phosphorylation and cytoplasmic retention of Yes-associated protein 1 (YAP1). YAP1, a transcriptional co-activator known for its role in multiple cellular processes including proliferation and survival, was found here to act as a molecular brake on CD8⁺ T cell cytotoxic function. By preventing YAP1 from translocating into the nucleus, mannose effectively releases this brake, empowering T cells to produce higher levels of granzyme B, interferon-gamma, and tumor necrosis factor-alpha—potent effector molecules critical for tumor cell killing.

The therapeutic implications of this finding are profound. When combined with anti-PD-1 immune checkpoint blockade, oral administration of B. animalis or mannose supplementation induced a synergistic antitumor response far exceeding the efficacy of either treatment alone. This synergy appears to stem from mannose’s capacity to reinvigorate exhausted CD8⁺ T cells within the tumor immune microenvironment, converting a previously cold and immunosuppressed niche into one rich with active cytotoxic lymphocytes. This dual modulation of immune cell intrinsic pathways and the gut microbial ecosystem positions mannose and B. animalis as promising adjuvants to overcome current limitations in immunotherapy-resistant melanoma cases.

Experts involved in the study expressed surprise at the potency of mannose, a metabolite widely considered metabolically inert from an immunological perspective. Their work highlights a previously unrecognized microbe-metabolite-immune axis, where microbial-derived small molecules directly regulate host T cell transcriptional programs through the Hippo-YAP1 signaling pathway. Beyond activating effector function, mannose supplementation was also observed to enrich other beneficial gut bacteria, suggesting a multifaceted mode of action that could favorably remodel the gut microbiota to sustain long-term immune competence.

This discovery opens exciting translational avenues. B. animalis is already recognized as a safe probiotic with widespread use across various dietary supplements and fermented food products. Its incorporation into melanoma treatment regimens could provide a low-cost, non-invasive adjunct therapy with an established safety profile. Alternatively, purified mannose, which is well-tolerated in humans and amenable to standardized dosing, might offer a more controlled and scalable therapeutic approach. Furthermore, the identification of YAP1 as a central regulatory node in CD8⁺ T cell function unveils a novel immunotherapeutic target that could inspire development of small molecule inhibitors or gene therapy strategies in cancer immunology.

The researchers emphasize the urgent need for clinical trials to validate these preclinical findings in melanoma patients, determine optimal dosing regimens, and evaluate the long-term impact on immune memory and resistance mechanisms. If successful, this probiotic-metabolite axis could revolutionize personalized cancer immunotherapy by harnessing and augmenting the intrinsic synergy between the gut microbiota and the host immune system.

In summary, this pioneering work reveals that Bifidobacterium animalis suppresses melanoma progression through mannose-mediated inhibition of YAP1 in CD8⁺ T cells, thus potentiating anti-PD-1 immune checkpoint therapy. The study not only elucidates key molecular mechanisms intertwining microbial metabolites with T cell biology but also charts a rational path toward safer, more effective treatments to improve patient outcomes in one of the deadliest skin cancers. The convergence of microbiology, immunology, and oncology exemplified here underscores the transformative potential of microbiome-inspired cancer therapeutics in the era of precision medicine.

Subject of Research: Not applicable

Article Title: Bifidobacterium animalis suppresses melanoma progression and activates anti-tumor immunity by inhibiting YAP1 expression in CD8+ T cells

News Publication Date: 6-May-2026

References:
DOI: 10.20892/j.issn.2095-3941.2025.0652

Image Credits: Cancer Biology & Medicine

Keywords: Melanoma, Bifidobacterium animalis, mannose, CD8+ T cells, YAP1, Hippo pathway, immune checkpoint inhibitors, anti-PD-1 therapy, tumor microenvironment, gut microbiome, immunotherapy resistance

At the core of this investigation lies the understanding that the gut microbiome is not merely a collection of bacteria inhabiting the gastrointestinal tract but rather a critical player in human health. The metabolites produced by gut microbes can have far-reaching effects, including modulation of immune responses. The study emphasizes how these microbial metabolites can enhance the immune system’s ability to detect and destroy cancer cells, thereby paving the way for potential therapeutic applications that leverage this microbiome-immune interplay.

One of the key findings presented in the study illustrates the various pathways through which gut microbial metabolites affect immune cell function. Short-chain fatty acids (SCFAs) emerged as significant players in this context. These metabolites, generated through the fermentation of dietary fibers, are known to regulate immune responses by promoting anti-inflammatory pathways and enhancing the differentiation of regulatory T cells. This process not only helps in suppressing chronic inflammation—a hallmark of many cancers—but also improves the body’s capacity to mount an effective immune response against tumors.

Moreover, the research highlights the potential of gut microbiota to impact the efficacy of cancer immunotherapies. As the field of immunotherapy gains momentum in the fight against cancer, understanding how microbial profiles influence treatment responses becomes crucial. Liu et al. present compelling evidence that specific gut bacteria can alter the effectiveness of immune checkpoint inhibitors, a class of drugs designed to unleash the immune system’s power against cancer. This adds a novel dimension to personalized medicine, suggesting that manipulating the gut microbiome could enhance therapeutic outcomes for patients.

The findings also raise important questions about diet and lifestyle interventions as methods to optimize gut health for cancer prevention and treatment. The traditional adage “you are what you eat” takes on a new meaning in light of this research, as dietary choices play a pivotal role in shaping the gut microbiome composition and, consequently, its function. By enriching the diet with prebiotics and probiotics, individuals might not only support their overall health but also potentially boost their immune defenses against cancer.

Another intriguing aspect of the study is the exploration of how specific microbial metabolites can influence cancer-related inflammation. Chronic inflammation is often cited as a precursor to various forms of cancer, and understanding how gut-derived compounds can modulate inflammatory responses could lead to innovative strategies for cancer prevention. Liu et al. provide a roadmap for future investigations aimed at elucidating these mechanisms, underscoring the importance of microbiome research in the context of oncology.

Furthermore, the study opens the door to investigating the role of the gut-brain axis in cancer progression. The intricate communication network between the gut microbiome and the central nervous system suggests that psychological and emotional factors could influence gastrointestinal health, which in turn affects immune responses against tumors. This holistic approach raises awareness of the multifaceted nature of cancer and invites further exploration into how mental health and emotional well-being intersect with physical health in the battle against the disease.

The findings from Liu et al. also provoke a reassessment of clinical practices surrounding cancer treatment. The traditional model of treating cancer often focuses solely on the tumor itself, sidelining the patient’s microbiota health. This research pushes for a paradigm shift that incorporates gut health assessments as part of routine cancer care. Specialized nutritional strategies that target microbiome modulation could soon become integrated into standard treatment protocols, a development that could revolutionize patient outcomes.

It’s crucial to recognize the limitations of the study as well. While the evidence suggests a strong correlation between gut microbial metabolites and immune modulation in cancer, causation is not fully established. Further longitudinal studies are necessary to determine the specific mechanisms through which these metabolites exert their effects on the immune system and cancer microenvironments. There is a pressing need for clinical trials to assess the utility of microbiome-based interventions in diverse cancer types, ensuring that future therapeutic strategies are not only effective but also safe.

Integration of findings into clinical practice will require collaboration between researchers, clinicians, and nutritionists. An interdisciplinary approach will facilitate the translation of basic research findings into actionable clinical guidelines, ultimately benefiting patients. Understanding each patient’s unique microbiome composition could soon become as routine as assessing tumor genetics, heralding a new era of truly personalized cancer treatment.

In conclusion, the study by Liu et al. represents a significant step forward in unraveling the complexities of the gut microbiome’s role in cancer immunomodulation. As this field of research continues to evolve, it promises to redefine our understanding of cancer biology and its interplay with human health. The implications for patient care, therapeutic strategies, and preventative measures are profound, offering a glimpse into a future where optimizing gut health could play a pivotal role in enhancing cancer prevention and treatment.

As scientists dig deeper into this fascinating field, the potential for discovering novel interventions based on gut microbial metabolism remains vast. The journey ahead includes not only making breakthroughs in understanding but also fostering innovations that could save lives, with the gut microbiome as a key ally in the fight against cancer. The significance of this research could extend well beyond oncology, emphasizing the importance of the microbiome in overall health and disease prevention.

As more studies emerge, the hope is that the connection between gut health and cancer risk becomes clearer, equipping healthcare providers with the tools necessary to improve patient outcomes. The narrative framed by Liu et al. will likely serve as a foundation for future research endeavors, ultimately integrating gut microbiome considerations into holistic approaches for cancer prevention and treatment.

With these exciting developments on the horizon, we may soon witness a transformation in both our understanding of cancer and our strategies for combatting it, all thanks to the ever-evolving dialogue between our gut microbiome and immune system.

Subject of Research: Gut microbial metabolites in cancer immunomodulation

Article Title: Gut microbial metabolites in cancer immunomodulation

Article References: Liu, H., Xiong, X., Zhu, W. et al. Gut microbial metabolites in cancer immunomodulation. Mol Cancer 25, 8 (2026). https://doi.org/10.1186/s12943-025-02521-5

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12943-025-02521-5

Keywords: gut microbiome, cancer, immunomodulation, microbial metabolites, personalized medicine, inflammation, treatment outcomes, dietary interventions.

Emerging research over the past decade has increasingly highlighted the gut microbiome as a critical player in human health and disease, extending well beyond its traditional role in digestion. However, the causal links between specific microbial metabolic processes and cancer-specific gene expression have remained largely speculative until now. This new study delivers a rigorous genetic approach to ascertain which bacterial metabolic pathways directly influence the expression of the chondrosarcoma associated gene 1 (CSAG1), a gene implicated in the pathology of this malignant tumor.

The investigation harnessed the power of two-sample bidirectional and multivariate Mendelian randomization (MR) analyses, using the largest genome-wide association studies (GWAS) dataset currently available for both gut microbiota metabolic pathways and CSAG1 expression metrics. Mendelian randomization, a technique increasingly valued for its ability to infer causality in epidemiology and molecular biology, uses genetic variants as instrumental variables, thereby mitigating confounding factors that typically obscure observational studies.

Initial univariate MR analysis revealed several gut microbial metabolic pathways that have a statistically significant causal influence on CSAG1 expression. Notably, pathways such as tetrapyrrole biosynthesis from glutamate—a key route in the creation of heme and related compounds—alongside menaquinol 6 biosynthesis, a process linked to vitamin K2 production, were found to robustly regulate CSAG1 activity. In addition, glycogen degradation II, 8-amino-7-oxononanoate biosynthesis (involved in biotin synthesis), taxadiene biosynthesis, glycolysis, and tRNA charging pathways also surfaced as significant causal contributors.

The complexity of microbial-host interactions warranted deeper scrutiny using multivariate MR analysis, which adjusts for interdependent effects between these pathways. This refined method confirmed that tetrapyrrole biosynthesis, menaquinol 6 biosynthesis, glycogen degradation II, glycolysis, and tRNA charging maintained a strong, independent causal effect on CSAG1 gene expression. Such findings underscore the notion that multiple metabolic routes within gut microbiota converge to modulate genes associated with chondrosarcoma progression.

Intriguingly, reverse MR analyses were conducted to explore potential feedback loops—whether CSAG1 expression could, in turn, influence gut microbiota metabolic pathways. The results decisively indicated no significant reverse causality, reinforcing the unidirectional effect of microbial metabolism on cancer-related gene expression. This clarification adds weight to the argument that microbial metabolic shifts may actively precipitate molecular changes leading to tumorigenesis rather than being a secondary effect of cancer progression.

These revelations propel our understanding beyond correlative associations, enabling the field to start disentangling a causal mechanistic narrative linking gut microbiota metabolism to cancer biology. The pathways implicated have well-recognized biochemical roles, such as tetrapyrrole metabolism’s engagement with heme synthesis, which is vital for cellular respiration and oxidative stress regulation, both processes heavily involved in cancer cell metabolism and growth.

The study also opens avenues for therapeutic innovation. Modulation of the gut microbiome’s metabolic capacities—whether through diet, probiotics, or targeted drugs—may represent a novel strategy to indirectly influence cancer gene expression profiles, potentially impacting tumor growth or susceptibility. By identifying specific metabolic pathways as drivers, interventions can be more precise, avoiding broad-spectrum microbiota alterations that currently characterize many microbiome-based therapies.

Moreover, the findings emphasize the importance of holistic approaches in oncology research that integrate microbiology, genetics, and metabolic biochemistry. The multidisciplinary application of Mendelian randomization illustrates the cutting-edge in investigative techniques, combining statistical genetics with molecular biology, a hybrid approach that is likely to become standard in dissecting complex disease etiologies.

Given the scarcity of effective treatments against chondrosarcoma, which often demonstrates resistance to conventional chemotherapy and radiotherapy, these insights hold translational potential. Understanding how gut microbiota influences gene expression in tumors could lead to biomarkers for early diagnosis or prognosis, facilitating more timely and individualized patient management.

It is worth noting that while Mendelian randomization provides strong evidence for causality, experimental validation through functional studies will be crucial for confirming these pathways’ roles mechanistically. The integration of microbiome analysis with tumor biopsies and gene expression studies in clinical cohorts stands as a natural next step.

This research also hints at the broader paradigm that gut microbiota are not passive inhabitants but active metabolic partners influencing distant tissues and disease states, extending the significance of microbiome research well into oncology.

In summary, this landmark study redefines how we conceptualize the gut microbiota’s role in cancer by establishing a causal framework linking microbial metabolic activities to the expression of oncogenes in chondrosarcoma. It not only advances the scientific understanding of tumor biology but heralds an era where microbiome-informed therapeutic approaches may transform outcomes for bone cancer patients, something previously thought to be beyond reach.

As the scientific community digests these revelations, future exploration into other cancer types and microbial metabolic pathways is anticipated, potentially revealing a universal principle of microbiome-cancer interplay governed by microbial metabolites’ influence on host gene regulation.

The convergence of genetics, microbiology, and oncology in this study exemplifies modern biomedical research’s power, cementing the gut microbiome as a frontier for novel diagnostic and therapeutic strategies in cancer.

Subject of Research: Causal relationships between gut microbiota metabolic pathways and gene expression in chondrosarcoma.

Article Title: Causal effect of gut microbiota metabolic pathways on CSAG1 expression in chondrosarcoma: a mendelian randomization analysis.

Article References:
Liu, X., Yang, S. & Liu, L. Causal effect of gut microbiota metabolic pathways on CSAG1 expression in chondrosarcoma: a mendelian randomization analysis. BMC Cancer 25, 852 (2025). https://doi.org/10.1186/s12885-025-14281-y

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14281-y

The human gut harbors trillions of microorganisms whose diverse metabolic activities profoundly impact host physiology. One of their critical roles, as this study elucidates, involves chemically modifying primary bile acids synthesized by the liver. Traditionally recognized for their role in lipid digestion and cholesterol metabolism, bile acids have emerged as potent signaling molecules. This research highlights how gut bacteria convert these primary molecules into a broad spectrum of secondary bile acids, many previously unidentified, expanding our understanding of microbiome-driven chemical diversity.

Dr. Chun-Jun Guo, co-senior author and immunologist at Weill Cornell, expresses enthusiasm over these findings, emphasizing the novelty of bile acids’ ability to interfere with the androgen receptor (AR), a nuclear receptor pivotal in regulating gene transcription in response to androgen hormones like testosterone. The study’s revelation that certain microbiota-derived bile acid derivatives act as antagonists to AR demonstrates an unprecedented cross-talk between microbial metabolism and host endocrine pathways.

The researchers employed sophisticated biochemical frameworks to map out more than fifty novel microbiota-modified bile acid structures, using advanced metabolomic profiling to characterize their unique steroid backbones and functional groups. This endeavor underscores the gut microbiota’s extraordinary synthetic capacity, as structural variants of bile acids mimic endogenous sex steroids closely enough to influence hormone receptor dynamics.

Intriguingly, the androgen receptor is expressed not only in reproductive tissues but also across specific immune cell populations, including cytotoxic CD8+ T lymphocytes, which play a central role in tumor surveillance and eradication. Prior studies hinted that AR suppression could invigorate these immune cells’ anti-tumor potency, yet a biochemically defined mechanism had eluded scientists until now.

Capitalizing on this insight, the investigators screened the identified bile acids for their AR-modulating effects, discovering four metabolites capable of antagonizing AR with high specificity. This interaction effectively blocks androgen binding, disrupting downstream signaling cascades that normally attenuate T cell-mediated immune responses within the tumor microenvironment.

The in vivo implications of this microbial-endocrine axis were validated in murine models bearing bladder cancer, where administration of these bile acid antagonists resulted in a marked enhancement of CD8+ T cell infiltration and cytotoxic function. The increase in T cell survival and effector activity contributed to robust tumor regression, signifying a profound immunotherapeutic potential derived from microbial metabolites rather than conventional pharmacological agents.

Dr. Nicholas Collins, co-senior author and immunology expert, highlights that these results establish a new paradigm in cancer immunology: gut microbiota-generated molecules can recalibrate systemic immune responses through hormonal receptor modulation. This synergy between microbial metabolism and host defense mechanisms showcases an intricate evolutionary partnership with therapeutic implications.

Moreover, collaboration between microbiologists, immunologists, and biochemists was integral to unraveling these complex interactions, illustrating the expanding utility of interdisciplinary approaches in microbiome research. Dr. David Artis, director at the Jill Roberts Institute, notes that such studies deepen our molecular grasp of host–microbe relationships, potentially revolutionizing multiple facets of medicine, from oncology to endocrinology.

Looking forward, the team envisions translating these findings into innovative treatments that either supplement patients with specific gut bacteria engineered to produce beneficial bile acids or directly administer these compounds as adjuvants to existing cancer therapies. This strategy might amplify treatment efficacy while reducing toxicity by targeting immune pathways naturally tuned through microbial-host co-evolution.

Despite these breakthroughs, critical questions remain unresolved. How dietary factors modulate microbial bile acid synthesis, and what systemic effects these androgen receptor-blocking bile acids exert in healthy individuals demand further exploration. The researchers are investing efforts to engineer gut microbes with controllable bile acid production, enabling precise dissection of their physiologic roles beyond oncology.

This study underscores the untapped potential of the microbiome as a source of bioactive metabolites capable of influencing fundamental receptor-mediated signaling pathways in humans. By illuminating bile acids’ dual roles as digestive agents and pivotal immunomodulators, this work paves the way for a renaissance in utilizing microbiota-derived molecules to harness the immune system’s full therapeutic potential against cancer.

In summary, the discovery that microbiota-modified bile acids can antagonize the androgen receptor to invigorate anti-tumor immunity heralds a paradigm shift in our understanding of host-microbe interactions. The prospect of leveraging these natural compounds to synergize with immunotherapies offers a visionary direction for future cancer treatment strategies, highlighting the microbiome’s profound influence on human health and disease.

Subject of Research: Interaction of microbiota-derived bile acids with the host androgen receptor and their role in enhancing anti-tumor immunity

Article Title: Microbiota-derived bile acids antagonize the host androgen receptor and drive anti-tumor immunity

News Publication Date: 15-Apr-2025

Image Credits: Credit: Sondii Image

Keywords: Bile, Androgen signaling, Acids, Discovery research, Immune receptors, Intestines

The foundational concept behind this research is the recognition of oncomicrobes—specific microorganisms that contribute to tumor development. A growing body of evidence indicates that certain gut bacteria, when in excess, can foster an inflammatory environment conducive to cancer progression. This study posits that by employing vaccines targeting these oncomicrobes, a powerful tool can be forged not only to mitigate tumor development but also to preserve the integrity of the beneficial gut microbiota that play essential roles in overall health.

Central to this study were two experimental mouse models. The first model focused on preventive strategies targeting the oncomicrobe Campylobacter jejuni, known for its pathogenic impact and association with CRC. The second model turned its attention towards Enterotoxigenic Bacteroides fragilis (ETBF), which has been identified as a significant contributor to CRC pathogenesis. Researchers meticulously developed and administered vaccines specific to each microbial target, aiming to demonstrate that induction of robust immune responses could effectively inhibit tumorigenesis.

Impressive findings emerged when the vaccine against C. jejuni demonstrated a marked reduction in the incidence of tumors among treated mice. This protective effect was accompanied by rapid clearance of the oncomicrobe from the gut, indicating not just a preventive but potentially therapeutic benefit as well. This result reinforces the potential of targeting specific microbial agents to inhibit cancer development effectively.

In the therapeutic context, the ETBF vaccine presented compelling evidence of efficacy. Tumor numbers significantly declined among vaccinated mice, and a notable restoration of beneficial gut bacteria was observed. Specifically, the abundance of non-toxic strains of Bacteroides fragilis increased, suggesting that the vaccine not only suppresses harmful microbial populations but also restores a healthier microbial balance. This dual-action presents a promising paradigm in CRC management, marrying tumor suppression with microbiota restoration.

A critical concern in the development of microbial-targeted therapies is the potential disruption of the gut microbiota—a delicate ecosystem essential for maintaining health. Remarkably, both vaccines demonstrated minimal disruption to the overall gut microbiota composition, suggesting a targeted approach that spares beneficial bacteria while eliminating pathogenic strains. This specificity is a cornerstone of effective immunotherapy, as it minimizes unintended consequences associated with more aggressive treatments, such as antibiotics.

The immune response elicited by these vaccines is noteworthy. Enhanced levels of antibodies and activated T cells played pivotal roles in tumor suppression. This finding underscores the importance of a well-coordinated immune attack against not just the tumor itself but the microbial agents that facilitate its growth and progression. The study highlights the potential for vaccination to prime the immune system to respond more vigorously when faced with tumor development.

Moreover, the vaccines appeared to influence the intestinal metabolome, which is the collection of metabolites produced by gut microbes. The vaccine targeting C. jejuni led to an increase in beneficial antitumor metabolites, accompanied by a decrease in those promoting tumor growth. This suggests that beyond direct action on microbes, these vaccines may modulate the broader metabolic landscape of the gut, creating an environment less conducive to cancer development.

Despite the promising data generated from this mouse study, translating these findings into effective human therapies requires caution and further investigation. Trials involving human subjects will be crucial in assessing the safety and effectiveness of such treatments. Yet, the implications of this research are profound. If validated in clinical settings, these vaccines could represent a groundbreaking addition to the current strategies employed in CRC prevention and treatment.

A significant aspect of this research is its focus on high-risk populations. Many individuals carry higher susceptibilities to CRC due to genetic predispositions or specific lifestyle risk factors. By tailoring vaccines to target the oncomicrobes prevalent in these high-risk groups, medical professionals could establish preventive strategies that are both innovative and effective.

In conclusion, the research surrounding oncomicrobial vaccines targeting C. jejuni and ETBF marks a significant advancement in the fight against colorectal cancer. The study offers a glimpse into the future of cancer immunotherapy, where vaccines do not just bolster immune defenses but specifically construct an environment that fosters health by targeting known threats. Further exploration and clinical application of these findings may revolutionize the preventive and therapeutic approaches to one of the most formidable cancers affecting global populations today.

Ultimately, the movement towards personalized and microbial-focused immunotherapies appears poised to reshape cancer treatment paradigms. The prospect of vaccines that target specific microbes, mitigate inflammation, and maintain microbial diversity heralds an exciting new era in our ongoing battle against cancer. As research progresses, continual adaptation and innovation within this field will be essential, positioning oncomicrobial vaccines as a beacon of hope in cancer prevention and therapy.

Subject of Research: Animals
Article Title: Oncomicrobial vaccines mitigate tumor progression via precisely targeting oncomicrobes in mice
News Publication Date: 7-Jan-2025
Web References: Protein & Cell
References: DOI link
Image Credits: Yudan Mao, Yan Li, Xianzun Xiao, Junrui Mai, Gan Lin, Sheng Liu, Jiayuan Huang, Xiangting Zhou, Xiangyu Mou, Wenjing Zhao
Keywords: Oncomicrobes, Colorectal Cancer, Vaccines, Immunotherapy, Gut Microbiota, Cancer Prevention, Tumor Suppression, Antibody Response, Metabolome, Therapeutic Models.